iShares Biotechnology ETF (IBB)

ETF ยท Nasdaq

iShares Biotechnology ETF (IBB) is an exchange-traded fund listed on Nasdaq, where it has traded since February 5, 2001.

Type
Exchange-traded fund
Listed On
Nasdaq
Listed Since
February 5, 2001

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 952 institutions reported holding IBB, with 40.0 million shares worth $7.6 billion in aggregate. The largest reported holder was Bank of America, with 6.9 million shares worth $1.3 billion. Of the 5 largest holders listed below, 2 added shares and 3 reduced their positions during the quarter.

InstitutionSharesValueQuarter change
Bank of America6,875,131$1.3BReduced 5.29%
Citigroup4,760,709$905MReduced 7.07%
Morgan Stanley3,320,977$632MAdded 19.74%
Bnp Paribas Financial Markets2,217,939$422MReduced 8.71%
Two Sigma Investments1,588,107$302MAdded 184.71%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is IBB?

iShares Biotechnology ETF (IBB) is an exchange-traded fund listed on Nasdaq, where it has traded since February 5, 2001.

Who are the largest institutional holders of IBB?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IBB were Bank of America, Citigroup and Morgan Stanley.

How many institutions own IBB?

952 institutions reported a position in IBB for the quarter ended June 30, 2026, worth $7.6 billion in total.

Did institutions buy or sell IBB last quarter?

Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter. Every reported holder and its change is on the SentiSense ownership page for IBB.

Every reported institutional holder, plus insider and congressional trades in IBB, on SentiSense.